BetterLife Pharma Achieves Key Cardiac Safety Milestone

BetterLife Pharma (TSE:BETR) has released an update.

BetterLife Pharma has announced promising cardiac safety data for its LSD derivative, BETR-001, which shows minimal impact on crucial cardiac ion channels. This positive outcome positions the company closer to initiating clinical trials, advancing its efforts in developing treatments for neuro-psychiatric and neurological disorders.

For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.